• LAST PRICE
    1.0000
  • TODAY'S CHANGE (%)
    Trending Up0.0100 (1.0101%)
  • Bid / Lots
    0.9700/ 5
  • Ask / Lots
    1.0200/ 12
  • Open / Previous Close
    1.0000 / 0.9900
  • Day Range
    Low 1.0000
    High 1.0000
  • 52 Week Range
    Low 0.6200
    High 5.6699
  • Volume
    15,445

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.99
TimeVolumeAPRE
09:32 ET66701
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAPRE
Aprea Therapeutics Inc
23.2M
-0.6x
---
United StatesPVCT
Provectus Biopharmaceuticals Inc
23.1M
-4.6x
---
United StatesSYN
Synthetic Biologics Inc
23.0M
-1.2x
---
United StatesRGRX
RegeneRx Biopharmaceuticals Inc
23.2M
-14.6x
---
United StatesRGLS
Regulus Therapeutics Inc
23.5M
-5.7x
---
United StatesTPST
Tempest Therapeutics Inc
23.5M
-0.2x
---
As of 2022-08-08

Company Information

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing and commercializing novel cancer therapeutics that reactivate mutant protein 53 (p53) tumor suppressor protein. The Company's lead product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes, or myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The Company's APR-548 is a second generation p53 reactivator that is a unique analog of eprenetapopt and therefore a pro-drug of MQ. APR-548 exhibits high oral bioavailability in preclinical testing and is being developed in an oral dosage form. The Company has initiated a Phase I clinical trial testing APR-548 in relapsed/refractory MDS and AML. Its solid tumor program includes its clinical trial evaluating eprenetapopt with anti-PD-1 therapy in advanced solid tumors.

Contact Information

Headquarters
535 Boylston StBOSTON, MA, United States 02116-3720
Phone
609-510-4718
Fax
302-655-5049

Executives

Chairman of the Board, Chief Executive Officer
Christian Schade
President, Director
Oren Gilad
Chief Financial Officer, Senior Vice President, Secretary
Scott Coiante
Chief Operating Officer, Senior Vice President
Gregory Korbel
Senior Vice President, Chief Scientific Officer
Lars Abrahmsen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$23.2M
Revenue (TTM)
$0.00
Shares Outstanding
23.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.65
Book Value
$2.26
P/E Ratio
-0.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.